VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Rationale for targeting leukemic stem cells with PDL1 antibodies or IRAK inhibitors

Toshio Kitamura, MD, PhD, The University of Tokyo, Tokyo, Japan, outlines the rationale for targeting leukemic stem cells with PDL1 antibodies or IRAK inhibitors in combination with imatinib in chronic myeloid leukemia (CML). Prof. Kitamura explains that leukemic stem cells have been shown to express PDL1 after imatinib treatment. Therefore, targeting PDL1 could improve the eradication of CML stem cells and increase the rate of patients eligible for treatment discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisor for Rigel.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter